TY - JOUR
T1 - Serglycin Is Involved in TGF-β Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue
AU - Tellez-Gabriel, Marta
AU - Tekpli, Xavier
AU - Reine, Trine M.
AU - Hegge, Beate
AU - Nielsen, Stephanie R.
AU - Chen, Meng
AU - Moi, Line
AU - Normann, Lisa Svartdal
AU - Busund, Lill Tove R.
AU - Calin, George A.
AU - Mælandsmo, Gunhild M.
AU - Perander, Maria
AU - Theocharis, Achilleas D.
AU - Kolset, Svein O.
AU - Knutsen, Erik
N1 - Publisher Copyright:
Copyright © 2022 Tellez-Gabriel, Tekpli, Reine, Hegge, Nielsen, Chen, Moi, Normann, Busund, Calin, Mælandsmo, Perander, Theocharis, Kolset and Knutsen.
PY - 2022/4/14
Y1 - 2022/4/14
N2 - Serglycin is a proteoglycan highly expressed by immune cells, in which its functions are linked to storage, secretion, transport, and protection of chemokines, proteases, histamine, growth factors, and other bioactive molecules. In recent years, it has been demonstrated that serglycin is also expressed by several other cell types, such as endothelial cells, muscle cells, and multiple types of cancer cells. Here, we show that serglycin expression is upregulated in transforming growth factor beta (TGF-β) induced epithelial-mesenchymal transition (EMT). Functional studies provide evidence that serglycin plays an important role in the regulation of the transition between the epithelial and mesenchymal phenotypes, and it is a significant EMT marker gene. We further find that serglycin is more expressed by breast cancer cell lines with a mesenchymal phenotype as well as the basal-like subtype of breast cancers. By examining immune staining and single cell sequencing data of breast cancer tissue, we show that serglycin is highly expressed by infiltrating immune cells in breast tumor tissue.
AB - Serglycin is a proteoglycan highly expressed by immune cells, in which its functions are linked to storage, secretion, transport, and protection of chemokines, proteases, histamine, growth factors, and other bioactive molecules. In recent years, it has been demonstrated that serglycin is also expressed by several other cell types, such as endothelial cells, muscle cells, and multiple types of cancer cells. Here, we show that serglycin expression is upregulated in transforming growth factor beta (TGF-β) induced epithelial-mesenchymal transition (EMT). Functional studies provide evidence that serglycin plays an important role in the regulation of the transition between the epithelial and mesenchymal phenotypes, and it is a significant EMT marker gene. We further find that serglycin is more expressed by breast cancer cell lines with a mesenchymal phenotype as well as the basal-like subtype of breast cancers. By examining immune staining and single cell sequencing data of breast cancer tissue, we show that serglycin is highly expressed by infiltrating immune cells in breast tumor tissue.
KW - breast cancer
KW - epithelial-mesenchymal transition (EMT)
KW - proteoglycans (PG)
KW - serglycin (SRGN)
KW - Single cell sequencing
KW - transforming growth factor beta (TGF- β)
KW - tumor infiltrating immune cells
UR - http://www.scopus.com/inward/record.url?scp=85128949780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128949780&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.868868
DO - 10.3389/fonc.2022.868868
M3 - Article
C2 - 35494005
AN - SCOPUS:85128949780
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 868868
ER -